The global Personalized Medicine and Epigenomics market size was valued at US$ million in 2023. With growing demand in downstream market, the Personalized Medicine and Epigenomics is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Personalized Medicine and Epigenomics market. Personalized Medicine and Epigenomics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Personalized Medicine and Epigenomics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Personalized Medicine and Epigenomics market.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Key Features:
The report on Personalized Medicine and Epigenomics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Personalized Medicine and Epigenomics market. It may include historical data, market segmentation by Type (e.g., Reagents, Kits), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Personalized Medicine and Epigenomics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Personalized Medicine and Epigenomics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Personalized Medicine and Epigenomics industry. This include advancements in Personalized Medicine and Epigenomics technology, Personalized Medicine and Epigenomics new entrants, Personalized Medicine and Epigenomics new investment, and other innovations that are shaping the future of Personalized Medicine and Epigenomics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Personalized Medicine and Epigenomics market. It includes factors influencing customer ' purchasing decisions, preferences for Personalized Medicine and Epigenomics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Personalized Medicine and Epigenomics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Personalized Medicine and Epigenomics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Personalized Medicine and Epigenomics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Personalized Medicine and Epigenomics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Personalized Medicine and Epigenomics market.
Market Segmentation:
Personalized Medicine and Epigenomics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Reagents
Kits
Instruments
Enzymes
Services
Segmentation by application
Oncology
Non-Oncology
Cancer Drug Technology
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Affymetrix
Agilent Technologies
Astellas Pharmaceuticals
BAYER AG
Bio Vision
Celgene Corp.
Emd Millipore
Epigenomics AG
Epigentex
Envivo Pharmaceuticals (Forum Pharmaceutricals)
Gilead Sciences
Glaxosmithkline
Illumina Inc.
Johnson & Johnson
Karus Therapeutics Limited
Laboratory Corp. Of America Holdings
LES Laboratoires Servier
Merck
Naturewise Biotech & Medicals Corp.
Novartis Pharma AG
Oncolys Biopharma Inc.
Orchid Chemicals & Pharmaceuticals Limited
Progen Pharmaceuticals Limited
Quest Diagnostics
Roche Holding AG
Rubicon Genomics
Takeda Pharmaceutical Company Limited
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Personalized Medicine and Epigenomics Market Size 2019-2030
2.1.2 Personalized Medicine and Epigenomics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Personalized Medicine and Epigenomics Segment by Type
2.2.1 Reagents
2.2.2 Kits
2.2.3 Instruments
2.2.4 Enzymes
2.2.5 Services
2.3 Personalized Medicine and Epigenomics Market Size by Type
2.3.1 Personalized Medicine and Epigenomics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Personalized Medicine and Epigenomics Market Size Market Share by Type (2019-2024)
2.4 Personalized Medicine and Epigenomics Segment by Application
2.4.1 Oncology
2.4.2 Non-Oncology
2.4.3 Cancer Drug Technology
2.5 Personalized Medicine and Epigenomics Market Size by Application
2.5.1 Personalized Medicine and Epigenomics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Personalized Medicine and Epigenomics Market Size Market Share by Application (2019-2024)
3 Personalized Medicine and Epigenomics Market Size by Player
3.1 Personalized Medicine and Epigenomics Market Size Market Share by Players
3.1.1 Global Personalized Medicine and Epigenomics Revenue by Players (2019-2024)
3.1.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Players (2019-2024)
3.2 Global Personalized Medicine and Epigenomics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Personalized Medicine and Epigenomics by Regions
4.1 Personalized Medicine and Epigenomics Market Size by Regions (2019-2024)
4.2 Americas Personalized Medicine and Epigenomics Market Size Growth (2019-2024)
4.3 APAC Personalized Medicine and Epigenomics Market Size Growth (2019-2024)
4.4 Europe Personalized Medicine and Epigenomics Market Size Growth (2019-2024)
4.5 Middle East & Africa Personalized Medicine and Epigenomics Market Size Growth (2019-2024)
5 Americas
5.1 Americas Personalized Medicine and Epigenomics Market Size by Country (2019-2024)
5.2 Americas Personalized Medicine and Epigenomics Market Size by Type (2019-2024)
5.3 Americas Personalized Medicine and Epigenomics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Personalized Medicine and Epigenomics Market Size by Region (2019-2024)
6.2 APAC Personalized Medicine and Epigenomics Market Size by Type (2019-2024)
6.3 APAC Personalized Medicine and Epigenomics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Personalized Medicine and Epigenomics by Country (2019-2024)
7.2 Europe Personalized Medicine and Epigenomics Market Size by Type (2019-2024)
7.3 Europe Personalized Medicine and Epigenomics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Personalized Medicine and Epigenomics by Region (2019-2024)
8.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2019-2024)
8.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Personalized Medicine and Epigenomics Market Forecast
10.1 Global Personalized Medicine and Epigenomics Forecast by Regions (2025-2030)
10.1.1 Global Personalized Medicine and Epigenomics Forecast by Regions (2025-2030)
10.1.2 Americas Personalized Medicine and Epigenomics Forecast
10.1.3 APAC Personalized Medicine and Epigenomics Forecast
10.1.4 Europe Personalized Medicine and Epigenomics Forecast
10.1.5 Middle East & Africa Personalized Medicine and Epigenomics Forecast
10.2 Americas Personalized Medicine and Epigenomics Forecast by Country (2025-2030)
10.2.1 United States Personalized Medicine and Epigenomics Market Forecast
10.2.2 Canada Personalized Medicine and Epigenomics Market Forecast
10.2.3 Mexico Personalized Medicine and Epigenomics Market Forecast
10.2.4 Brazil Personalized Medicine and Epigenomics Market Forecast
10.3 APAC Personalized Medicine and Epigenomics Forecast by Region (2025-2030)
10.3.1 China Personalized Medicine and Epigenomics Market Forecast
10.3.2 Japan Personalized Medicine and Epigenomics Market Forecast
10.3.3 Korea Personalized Medicine and Epigenomics Market Forecast
10.3.4 Southeast Asia Personalized Medicine and Epigenomics Market Forecast
10.3.5 India Personalized Medicine and Epigenomics Market Forecast
10.3.6 Australia Personalized Medicine and Epigenomics Market Forecast
10.4 Europe Personalized Medicine and Epigenomics Forecast by Country (2025-2030)
10.4.1 Germany Personalized Medicine and Epigenomics Market Forecast
10.4.2 France Personalized Medicine and Epigenomics Market Forecast
10.4.3 UK Personalized Medicine and Epigenomics Market Forecast
10.4.4 Italy Personalized Medicine and Epigenomics Market Forecast
10.4.5 Russia Personalized Medicine and Epigenomics Market Forecast
10.5 Middle East & Africa Personalized Medicine and Epigenomics Forecast by Region (2025-2030)
10.5.1 Egypt Personalized Medicine and Epigenomics Market Forecast
10.5.2 South Africa Personalized Medicine and Epigenomics Market Forecast
10.5.3 Israel Personalized Medicine and Epigenomics Market Forecast
10.5.4 Turkey Personalized Medicine and Epigenomics Market Forecast
10.5.5 GCC Countries Personalized Medicine and Epigenomics Market Forecast
10.6 Global Personalized Medicine and Epigenomics Forecast by Type (2025-2030)
10.7 Global Personalized Medicine and Epigenomics Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Information
11.1.2 Abbott Laboratories Personalized Medicine and Epigenomics Product Offered
11.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Abbott Laboratories Main Business Overview
11.1.5 Abbott Laboratories Latest Developments
11.2 Affymetrix
11.2.1 Affymetrix Company Information
11.2.2 Affymetrix Personalized Medicine and Epigenomics Product Offered
11.2.3 Affymetrix Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Affymetrix Main Business Overview
11.2.5 Affymetrix Latest Developments
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Information
11.3.2 Agilent Technologies Personalized Medicine and Epigenomics Product Offered
11.3.3 Agilent Technologies Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Agilent Technologies Main Business Overview
11.3.5 Agilent Technologies Latest Developments
11.4 Astellas Pharmaceuticals
11.4.1 Astellas Pharmaceuticals Company Information
11.4.2 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Product Offered
11.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Astellas Pharmaceuticals Main Business Overview
11.4.5 Astellas Pharmaceuticals Latest Developments
11.5 BAYER AG
11.5.1 BAYER AG Company Information
11.5.2 BAYER AG Personalized Medicine and Epigenomics Product Offered
11.5.3 BAYER AG Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 BAYER AG Main Business Overview
11.5.5 BAYER AG Latest Developments
11.6 Bio Vision
11.6.1 Bio Vision Company Information
11.6.2 Bio Vision Personalized Medicine and Epigenomics Product Offered
11.6.3 Bio Vision Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Bio Vision Main Business Overview
11.6.5 Bio Vision Latest Developments
11.7 Celgene Corp.
11.7.1 Celgene Corp. Company Information
11.7.2 Celgene Corp. Personalized Medicine and Epigenomics Product Offered
11.7.3 Celgene Corp. Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Celgene Corp. Main Business Overview
11.7.5 Celgene Corp. Latest Developments
11.8 Emd Millipore
11.8.1 Emd Millipore Company Information
11.8.2 Emd Millipore Personalized Medicine and Epigenomics Product Offered
11.8.3 Emd Millipore Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Emd Millipore Main Business Overview
11.8.5 Emd Millipore Latest Developments
11.9 Epigenomics AG
11.9.1 Epigenomics AG Company Information
11.9.2 Epigenomics AG Personalized Medicine and Epigenomics Product Offered
11.9.3 Epigenomics AG Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Epigenomics AG Main Business Overview
11.9.5 Epigenomics AG Latest Developments
11.10 Epigentex
11.10.1 Epigentex Company Information
11.10.2 Epigentex Personalized Medicine and Epigenomics Product Offered
11.10.3 Epigentex Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Epigentex Main Business Overview
11.10.5 Epigentex Latest Developments
11.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
11.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Information
11.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Product Offered
11.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Main Business Overview
11.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Latest Developments
11.12 Gilead Sciences
11.12.1 Gilead Sciences Company Information
11.12.2 Gilead Sciences Personalized Medicine and Epigenomics Product Offered
11.12.3 Gilead Sciences Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Gilead Sciences Main Business Overview
11.12.5 Gilead Sciences Latest Developments
11.13 Glaxosmithkline
11.13.1 Glaxosmithkline Company Information
11.13.2 Glaxosmithkline Personalized Medicine and Epigenomics Product Offered
11.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Glaxosmithkline Main Business Overview
11.13.5 Glaxosmithkline Latest Developments
11.14 Illumina Inc.
11.14.1 Illumina Inc. Company Information
11.14.2 Illumina Inc. Personalized Medicine and Epigenomics Product Offered
11.14.3 Illumina Inc. Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Illumina Inc. Main Business Overview
11.14.5 Illumina Inc. Latest Developments
11.15 Johnson & Johnson
11.15.1 Johnson & Johnson Company Information
11.15.2 Johnson & Johnson Personalized Medicine and Epigenomics Product Offered
11.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Johnson & Johnson Main Business Overview
11.15.5 Johnson & Johnson Latest Developments
11.16 Karus Therapeutics Limited
11.16.1 Karus Therapeutics Limited Company Information
11.16.2 Karus Therapeutics Limited Personalized Medicine and Epigenomics Product Offered
11.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Karus Therapeutics Limited Main Business Overview
11.16.5 Karus Therapeutics Limited Latest Developments
11.17 Laboratory Corp. Of America Holdings
11.17.1 Laboratory Corp. Of America Holdings Company Information
11.17.2 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Product Offered
11.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Laboratory Corp. Of America Holdings Main Business Overview
11.17.5 Laboratory Corp. Of America Holdings Latest Developments
11.18 LES Laboratoires Servier
11.18.1 LES Laboratoires Servier Company Information
11.18.2 LES Laboratoires Servier Personalized Medicine and Epigenomics Product Offered
11.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 LES Laboratoires Servier Main Business Overview
11.18.5 LES Laboratoires Servier Latest Developments
11.19 Merck
11.19.1 Merck Company Information
11.19.2 Merck Personalized Medicine and Epigenomics Product Offered
11.19.3 Merck Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Merck Main Business Overview
11.19.5 Merck Latest Developments
11.20 Naturewise Biotech & Medicals Corp.
11.20.1 Naturewise Biotech & Medicals Corp. Company Information
11.20.2 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Product Offered
11.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 Naturewise Biotech & Medicals Corp. Main Business Overview
11.20.5 Naturewise Biotech & Medicals Corp. Latest Developments
11.21 Novartis Pharma AG
11.21.1 Novartis Pharma AG Company Information
11.21.2 Novartis Pharma AG Personalized Medicine and Epigenomics Product Offered
11.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.21.4 Novartis Pharma AG Main Business Overview
11.21.5 Novartis Pharma AG Latest Developments
11.22 Oncolys Biopharma Inc.
11.22.1 Oncolys Biopharma Inc. Company Information
11.22.2 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Product Offered
11.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.22.4 Oncolys Biopharma Inc. Main Business Overview
11.22.5 Oncolys Biopharma Inc. Latest Developments
11.23 Orchid Chemicals & Pharmaceuticals Limited
11.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Information
11.23.2 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Product Offered
11.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.23.4 Orchid Chemicals & Pharmaceuticals Limited Main Business Overview
11.23.5 Orchid Chemicals & Pharmaceuticals Limited Latest Developments
11.24 Progen Pharmaceuticals Limited
11.24.1 Progen Pharmaceuticals Limited Company Information
11.24.2 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Product Offered
11.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.24.4 Progen Pharmaceuticals Limited Main Business Overview
11.24.5 Progen Pharmaceuticals Limited Latest Developments
11.25 Quest Diagnostics
11.25.1 Quest Diagnostics Company Information
11.25.2 Quest Diagnostics Personalized Medicine and Epigenomics Product Offered
11.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.25.4 Quest Diagnostics Main Business Overview
11.25.5 Quest Diagnostics Latest Developments
11.26 Roche Holding AG
11.26.1 Roche Holding AG Company Information
11.26.2 Roche Holding AG Personalized Medicine and Epigenomics Product Offered
11.26.3 Roche Holding AG Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.26.4 Roche Holding AG Main Business Overview
11.26.5 Roche Holding AG Latest Developments
11.27 Rubicon Genomics
11.27.1 Rubicon Genomics Company Information
11.27.2 Rubicon Genomics Personalized Medicine and Epigenomics Product Offered
11.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.27.4 Rubicon Genomics Main Business Overview
11.27.5 Rubicon Genomics Latest Developments
11.28 Takeda Pharmaceutical Company Limited
11.28.1 Takeda Pharmaceutical Company Limited Company Information
11.28.2 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Product Offered
11.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2019-2024)
11.28.4 Takeda Pharmaceutical Company Limited Main Business Overview
11.28.5 Takeda Pharmaceutical Company Limited Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.